Wednesday, July 15, 2020 PRIMARY PUBLICATION CCTG CO.26: A Phase II Randomized Study of Durvalumab and Tremelimumab and Best Supportive Care vs Best Supportive Care Alone in Patients with Advanced Colorectal Adenocarcinoma Refractory to Standard Therapies Chen EX, Jonker DJ, Loree JM, Kennecke HF, Berry SR, Couture F, Ahmad CE, Goffin JR, Kavan P, Harb M, Colwell B, Samimi S, Samson B, Abbas T, Aucoin N, Aubin F, Koski SL, Wei AC, Magoski NM, Tu D, O'Callaghan CJ. Effect of Combined Immune Checkpoint Inhibition vs Best Supportive Care Alone in Patients With Advanced Colorectal Cancer: The Canadian Cancer Trials Group CO.26 Study. JAMA Oncology e200910, 2020. Results of this study found that combined immune checkpoint inhibition with durvalumab plus tremelimumab may be associated with prolonged overall survival in patients with advanced refractory CRC. Elevated plasma TMB may select patients most likely to benefit. Further confirmation studies are warranted. https://pubmed.ncbi.nlm.nih.gov/32379280/ TRIAL-RELATED PUBLICATIONS CCTG LY.12: A Phase III Study of Gemcitabine, Dexamethasone, and Cisplatin Compared to Dexamethasone, Cytarabine, and Cisplatin Plus/Minus Rituximab [(R) -GDP VS (R) -DHAP] as Salvage Chemotherapy for Patients with Relapsed or Refractory Aggressive Histology Non-Hodgkin's Lymphoma Prior to Autologous Stem Cell Transplant and Followed by Maintenance Rituximab Versus Observation Assouline S, Li S, Gisselbrecht C, Fogarty P, Hay A, Van Den Neste E, Shepherd LE, Schmitz N, Baetz T, Keating A, Robinson S, Seftel M, Stelitano C, Djurfeldt MS, Meyer R, Chen BE, Crump M. The conditional survival analysis of relapsed DLBCL after autologous transplant: a subgroup analysis of LY.12 and CORAL. Blood advances 4: 2011-7, 2020. https://pubmed.ncbi.nlm.nih.gov/32396614/ MAP.3: A Phase III Randomized Study of Exemestane Versus Placebo in Postmenopausal Women at Increased Risk of Developing Breast Cancer Richardson H, Ho V, Pasquet R, Singh RJ, Goetz MP, Tu D, Goss PE, Ingle JN, on behalf of the MAP. Baseline estrogen levels in postmenopausal women participating in the MAP.3 breast cancer chemoprevention trial. Menopause 27: 693-700, 2020. https://pubmed.ncbi.nlm.nih.gov/32433262/ GENERAL ARTICLE Chen L, Tyryshkin K, Moore A, Scott DW, Steidl C, Li Y, Shepherd LE, Rauh M, Deng L, Good D, Virk S, Chen BE, Crocker S, Baetz T, LeBrun DP. Objective quantification of BCL2 protein by multiplex immunofluorescence in routine biopsy samples of diffuse large B-cell lymphoma demonstrates associations with survival and BCL2 gene alterations. Leuk Lymphoma 61: 1334-44, 2020. https://pubmed.ncbi.nlm.nih.gov/31942813/
